Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 5,818 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: EXTEND Clear all
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)

NCT04921969
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
2 Years to 11 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
64
States / cities
Birmingham, Alabama • Hoover, Alabama • Gilbert, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 18, 2026, 2:05 PM EDT
Withdrawn Phase 2 Interventional

Immediate Release Torsemide Versus Extended Release Torsemide After Salty Meal

NCT06176794
View directory record Official record
Conditions
Heart Failure
Interventions
Immediate release torsemide 20mg tablet, Extended release torsemide 24mg tablet
Drug
Lead sponsor
Sarfez Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 18, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

NCT00084656
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
ipilimumab, Tyrosinase/gp100/MART-1 Peptides
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 120 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 18, 2026, 2:05 PM EDT
Completed Phase 3 Interventional Results available

Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily.

NCT01962922
View directory record Official record
Conditions
Renal Failure
Interventions
LCP-Tacro, Tacrolimus -IR
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Chicago, Illinois • St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 18, 2026, 2:05 PM EDT
Terminated Phase 3 Interventional Results available

A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease

NCT02956486
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Elenbecestat, Placebo
Drug
Lead sponsor
Eisai Co., Ltd.
Industry
Eligibility
50 Years to 85 Years
Enrollment
2,212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
88
States / cities
Chandler, Arizona • Colton, California • Costa Mesa, California + 68 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 18, 2026, 2:05 PM EDT
Completed Not applicable Interventional

Study of Default Options in Advance Directives

NCT01817686
View directory record Official record
Conditions
COPD, Severe or Very Severe Airflow Obstruction and/or Receiving or Eligible to Receive Long-term Oxygen Therapy, Idiopathic Pulmonary Fibrosis, Other Interstitial Lung Disease Without Curative Therapy, Congestive Heart Failure, NYHA Class IV or NYHA Class III Plus 1 Hospitalization in the Past Year, Malignancy, Any Stage 3B or 4 Solid Tumor
Interventions
Comfort Default AD forms, Life Extension Default AD forms, Standard Default AD forms
Other
Lead sponsor
Corporal Michael J. Crescenz VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Oct 18, 2026, 2:05 PM EDT
Completed Phase 3 Interventional Results available

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis

NCT02660580
View directory record Official record
Conditions
Psoriasis, Plaque Type Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions
MSB11022, Humira®
Drug
Lead sponsor
Fresenius Kabi SwissBioSim GmbH
Industry
Eligibility
18 Years and older
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
San Luis Obispo, California • Coral Gables, Florida • West Palm Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Oct 18, 2026, 2:05 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens

NCT05217927
View directory record Official record
Conditions
Migraine
Interventions
Rimegepant 75mg daily dosing, Rimegepant 75mg every other day dosing, Placebo comparator dosing
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
30
States / cities
Tempe, Arizona • Colton, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 18, 2026, 2:05 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual Bleeding

NCT01280981
View directory record Official record
Conditions
Menorrhagia
Interventions
Tranexamic acid
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
92
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2011 · Synced Oct 18, 2026, 2:05 PM EDT
Completed Phase 1 Interventional

A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone

NCT02019329
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, RO5545965, risperidone
Other · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 18, 2026, 2:05 PM EDT
Completed Phase 3 Interventional

Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia

NCT00232037
View directory record Official record
Conditions
Dyspepsia
Interventions
Tegaserod
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older · Female only
Enrollment
359 participants
Timeline
2004 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 1, 2008 · Synced Oct 18, 2026, 2:05 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease

NCT01042977
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Cardiovascular Disease, Inadequate Glycaemic Control
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
45 Years and older
Enrollment
964 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
57
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 54 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2014 · Synced Oct 18, 2026, 2:05 PM EDT
Recruiting Not applicable Interventional

NiteCAPP: Web-based Interventions for Insomnia in Rural Dementia Caregivers

NCT04896775
View directory record Official record
Conditions
Insomnia, Dementia
Interventions
NiteCAPP CARES, NiteCAPP SHARES
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 18, 2026, 2:05 PM EDT
Completed Phase 3 Interventional

A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

NCT05463731
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Remternetug (IV), Remternetug (SC), Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years to 85 Years
Enrollment
1,667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
73
States / cities
Chandler, Arizona • Canoga Park, California • Carlsbad, California + 66 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 18, 2026, 2:05 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Abatacept in Patients With Active Crohn's Disease

NCT00406653
View directory record Official record
Conditions
Crohn's Disease
Interventions
abatacept, placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
37
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2010 · Synced Oct 18, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa

NCT03836001
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
Serlopitant Tablet, Placebo Oral Tablet
Drug
Lead sponsor
Stanford University
Other
Eligibility
13 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 18, 2026, 2:05 PM EDT
Completed No phase listed Observational

Intervention Nurses Start Infants Growing on Healthy Trajectories (INSIGHT) - Long Term Follow-Up

NCT03555331
View directory record Official record
Conditions
Child Obesity
Interventions
Child Safety Control Intervention, Responsive Parenting Intervention
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
Not listed
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Hershey, Pennsylvania • State College, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 18, 2026, 2:05 PM EDT
Recruiting Phase 3 Interventional

Intervention to Increase Intention to Change Alcohol/Tobacco Use in Veterans With Chronic Disease

NCT07039175
View directory record Official record
Conditions
Tobacco Smoking, Alcohol-Related Disorders
Interventions
MINDSET, Usual Care
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 18, 2026, 2:05 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Influence of 3D Printed Prostheses on Neural Activation Patterns

NCT04110730
View directory record Official record
Conditions
Amniotic Band Syndrome, Upper Extremity Deformities, Congenital
Interventions
3D Printed Upper-limb Prosthesis, Home Intervention
Device · Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
3 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 18, 2026, 2:05 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Virtual Tai ji Quan Exercise to Prevent Falls in Older Adults

NCT05822466
View directory record Official record
Conditions
Accidental Fall
Interventions
Virtual tai ji quan: moving for better balance intervention (V-TJQMBB), Virtual multimodal exercise intervention (V-Multimodal)
Behavioral
Lead sponsor
Oregon Research Institute
Other
Eligibility
65 Years to 90 Years
Enrollment
620 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Springfield, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 18, 2026, 2:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Post-operative Patient Positioning Device for Improvement of Post-Operative Pain

NCT04797637
View directory record Official record
Conditions
Pain, Postoperative
Interventions
ABBy® Adjustable Panniculus Retractor for Wound Care
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
278 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 18, 2026, 2:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Sequenced Behavioral and Medication Intervention for Cocaine Dependence

NCT01986075
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Computer-assisted behavior therapy, Mixed-Amphetamine Salts- Extended Release (MAS-ER), Placebo
Behavioral · Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Oct 18, 2026, 2:05 PM EDT
Completed Phase 3 Interventional Results available

A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate

NCT00740051
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Linagliptin, Linagliptin Placebo, Glimepiride
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
15
States / cities
Birmingham, Alabama • Peoria, Arizona • Greenbrae, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 18, 2026, 2:05 PM EDT
Completed Phase 3 Interventional

Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1

NCT05832931
View directory record Official record
Conditions
Secondary Hyperparathyroidism, End-stage Kidney Disease (ESKD)
Interventions
PLS240, Placebo, Open-Label Extension PLS240
Drug
Lead sponsor
Pathalys Pharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
49
States / cities
Pine Bluff, Arkansas • Anaheim, California • Beverly Hills, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 18, 2026, 2:05 PM EDT